In addition, the cases of liver fibrosis, the incidence of adverse reactions, and serum TNF-α and IL-6 expression levels in the experimental group were significantly lower than those in the control group (p < 0.05), which was similar to the results of Ren et al. [21] who have pointed in their study that entecavir combined with adefovir dipivoxil has significantly better efficacy in reducing HBeAg-negative chronic hepatitis B than entecavir alone. Here, IL6 is linked to Hepatic fibrosis.